russjcardiolРоссийский кардиологический журналRussian Journal of Cardiology1560-40712618-7620«SILICEA-POLIGRAF» LLC10.15829/1560-4071-2025-6652KMJCTErussjcardiol-6652Research ArticleФИБРИЛЛЯЦИЯ ПРЕДСЕРДИЙATRIAL FIBRILLATIONФибрилляция предсердий как полигенное заболевание современности (обзор)Atrial fibrillation as a modern polygenic disease: a literature reviewhttps://orcid.org/0000-0001-5837-7255СтребковаЕ. Д.StrebkovaE. D.

Стребкова Елизавета Дмитриевна — к.м.н., н.с. аритмологического отделаул. Большая Серпуховская, д. 27, Москва, 115093

Bolshaya Serpukhovskaya str., 27, Moscow, 115093

elizabeth.strebkova@yandex.ruhttps://orcid.org/0000-0001-7065-0250АртюхинаЕ. А.ArtyukhinaE. A.

Артюхина Елена Александровна — д.м.н., профессор, руководитель отделения электрофизиологических рентгенэндоваскулярных методов диагностики и лечения аритмий, ФГБУ Национальный медицинский исследовательский центр хирургии им. А. В. Вишневского Минздрава; профессор кафедры ангиологии, сердечно-­сосудистой, эндоваскулярной хирургии и аритмологии им. акад. А. В. Покровского, ФГБОУ ДПО Российская медицинская академия непрерывного профессионального образования Минздра­ва Россииул. Большая Серпуховская, д. 27, Москва, 115093, ул. Баррикадная, д. 2/1, стр. 1, Москва, 125993  

 

Bolshaya Serpukhovskaya str., 27, Moscow, 115093, 

Barricadnaya str., 2/1, bld. 1, Moscow, 125993

artelena.71@mail.ruhttps://orcid.org/0000-0003-1791-9163РевишвилиА. Ш.RevishviliA. Sh.

Ревишвили Амиран Шотаевич — академик РАН, д.м.н., профессор, директор, ФГБУ Национальный медицинский исследовательский центр хирургии им. А. В. Вишневского Минздрава; зав. кафедрой ангиологии, сердечно-­сосудистой, эндоваскулярной хирургии и аритмологии им. акад. А. В. Покровского, ФГБОУ ДПО Российская медицинская академия непрерывного профессионального образования Минздра­ва России

ул. Большая Серпуховская, д. 27, Москва, 115093, 

ул. Баррикадная, д. 2/1, стр. 1, Москва, 125993

Bolshaya Serpukhovskaya str., 27, Moscow, 115093, 

Barricadnaya str., 2/1, bld. 1, Moscow, 125993

amirevi@mail.ruФГБУ Национальный медицинский исследовательский центр хирургии им. А. В. Вишневского Минздрава РоссииРоссияVishnevsky National Medical Research Center of SurgeryRussian FederationФГБУ Национальный медицинский исследовательский центр хирургии им. А. В. Вишневского Минздрава; ФГБОУ ДПО Российская медицинская академия непрерывного профессионального образования Минздра­ва РоссииРоссияVishnevsky National Medical Research Center of Surgery; Russian Medical Academy of Continuous Professional EducationRussian Federation202522032026304SОбразование66526652Copyright © Стребкова Е.Д., Артюхина Е.А., Ревишвили А.Ш., 20262026Стребкова Е.Д., Артюхина Е.А., Ревишвили А.Ш.Strebkova E.D., Artyukhina E.A., Revishvili A.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://russjcardiol.elpub.ru/jour/article/view/6652

Ведущими факторами риска развития фибрилляции предсердий (ФП) являются пожилой возраст, структурные заболевания сердца, высокое артериальное давление и чрезмерное употребление алкоголя. В других случаях предикторы развития ФП установить невозможно, что отражает генетическую основу ФП. Генетическая предрасположенность на 40% увеличивает риск развития ФП в молодом возрасте. Важно отметить, что ФП не является строго наследственным заболеванием, а относится к мультифакторным заболеваниям. На сегодняшний день установлено более 160 генетических локусов, ассоциированных с ФП по результатам нескольких исследований, в частности GWAS (Genome-Wide Association Studies). Благодаря данным исследованиям стало понятно, что ФП имеет сложную генетическую архитектуру. Изучение генетической основы ФП может привести к выявлению новых молекулярных механизмов ФП и, как следствие, способно улучшить качество существующих методов лечения и разработать новые направления терапевтического лечения изолированных форм ФП, обеспечив более персонализированный подход и снизив затраты системы здравоохранения. Целью представленного литературного обзора явилось представление последних достижений и открытий в области генетического полиморфизма ФП.

The leading risk factors for atrial fibrillation (AF) include advanced age, structural heart disease, high blood pressure, and excessive alcohol use. In other cases, predictors of AF cannot be identified, reflecting the genetic basis of AF. Genetic predisposition increases the risk of AF at a young age by 40%. AF is not strictly hereditary but rather a multifactorial disorder. To date, more than 160 AF-associated genetic loci have been identified based on several studies, including Genome-Wide Association Studies (GWAS). These studies have revealed that AF has a complex genetic architecture. Studying the genetic basis of AF may identify new molecular mechanisms of AF and, as a result, may improve the quality of existing treatments and develop novel therapeutic approaches for isolated AF. This can ensure a more personalized approach and reducing healthcare costs. The aim of this literature review is to present the latest advances and discoveries in the field of AF genetic polymorphism.

фибрилляция предсердийгенетикаполигенностьфакторы рискаatrial fibrillationgeneticspolygenicityrisk factorsReferencesVan Gelder IC, Rienstra M, Bunting KV, et al. ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314-414. doi:10.1093/eurheartj/ehae176.Van Gelder IC, Rienstra M, Bunting KV, et al. ESC Scientific Document Group. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024;45(36):3314-414. doi:10.1093/eurheartj/ehae176.Potpara T, Romiti GF, Sohns C. The 2024 European Society of Cardiology Guidelines for Diagnosis and Management of Atrial Fibrillation: A Viewpoint from a Practicing Clinician’s Perspective. Thromb Haemost. 2024;124(12):1087-94. doi:10.1055/a-2434-9244.Potpara T, Romiti GF, Sohns C. The 2024 European Society of Cardiology Guidelines for Diagnosis and Management of Atrial Fibrillation: A Viewpoint from a Practicing Clinician’s Perspective. Thromb Haemost. 2024;124(12):1087-94. doi:10.1055/a-2434-9244.Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int J Stroke. 2021;16:217-21. doi:10.1177/1747493019897870.Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: An increasing epidemic and public health challenge. Int J Stroke. 2021;16:217-21. doi:10.1177/1747493019897870.Brundel BJJM, Ai X, Hills MT, et al. Atrial fibrillation. Nat Rev Dis Primers. 2022;8(1):21. doi:10.1038/s41572-022-00347-9.Brundel BJJM, Ai X, Hills MT, et al. Atrial fibrillation. Nat Rev Dis Primers. 2022;8(1):21. doi:10.1038/s41572-022-00347-9.Ревишвили А.Ш., Кадырова М., Стребкова Е.Д. и др. Ампутация ушка левого предсердия с использованием эндостеплера при торакоскопической аблации фибрилляции предсердий. Комплексные проблемы сердечнососудистых заболеваний. 2023;12(1):58-71. doi:10.17802/2306-1278-2023-12-1-58-71.Revishvili ASh, Kadirova M, Strebkova ED, et al. Left atrial appendage exclusion using a stapler with thoracoscopic ablation of atrial fibrillation. Complex Issues of Cardiovascular Diseases. 2023;12(1):58-71. (In Russ.) doi:10.17802/2306-1278-2023-12-1-58-71.Roselli C, Rienstra M, Ellinor PT. Genetics of Atrial Fibrillation in 2020: GWAS, Genome Sequencing, Polygenic Risk, and Beyond. Circ Res. 2020;127(1):21-33. doi:10.1161/CIRCRESAHA.120.316575.Roselli C, Rienstra M, Ellinor PT. Genetics of Atrial Fibrillation in 2020: GWAS, Genome Sequencing, Polygenic Risk, and Beyond. Circ Res. 2020;127(1):21-33. doi:10.1161/CIRCRESAHA.120.316575.Wolff L. Familial auricular fibrillation. N Engl J Med. 1943;229:396-8.Wolff L. Familial auricular fibrillation. N Engl J Med. 1943;229:396-8.Chen Y-H, Xu S-J, Bendahhou S, et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science. 2003;299:251-4.Chen Y-H, Xu S-J, Bendahhou S, et al. KCNQ1 gain-of-function mutation in familial atrial fibrillation. Science. 2003;299:251-4.Wijesurendra RS, Casadei B. Mechanisms of atrial fibrillation. Heart. 2019;105(24):1860-7. doi:10.1136/heartjnl-2018-314267.Wijesurendra RS, Casadei B. Mechanisms of atrial fibrillation. Heart. 2019;105(24):1860-7. doi:10.1136/heartjnl-2018-314267.Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271(11):840-4.Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271(11):840-4.Roselli C, Surakka I, Olesen MS, et al. Meta-analysis of genome-wide associations and polygenic risk prediction for atrial fibrillation in more than 180,000 cases. Nat Genet. 2025;57(3):539-47. doi:10.1038/s41588-024-02072-3.Roselli C, Surakka I, Olesen MS, et al. Meta-analysis of genome-wide associations and polygenic risk prediction for atrial fibrillation in more than 180,000 cases. Nat Genet. 2025;57(3):539-47. doi:10.1038/s41588-024-02072-3.Haïssaguerre M, Jaïs P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339(10):659-66. doi:10.1056/NEJM199809033391003.Haïssaguerre M, Jaïs P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339(10):659-66. doi:10.1056/NEJM199809033391003.Артюхина Е.А., Таймасова И.А., Ревишвили А.Ш. Катетерная аблация предсердных аритмий у пациентов после торакоскопической аблации персистирующих форм фибрилляции предсердий. Российский кардиологический журнал. 2020;25(7):3655. doi:10.15829/1560-4071-2020-3655.Artyukhina EA, Taymasova IA, Revishvili ASh. Catheter ablation of atrial arrhythmias in patients after thoracoscopic ablation of persistent atrial fibrillation. Russian Journal of Cardiology. 2020;25(7):3655. (In Russ.) doi:10.15829/1560-4071-2020-3655.Papathanasiou KA, Giotaki SG, Vrachatis DA, et al. Molecular Insights in Atrial Fibrillation Pathogenesis and Therapeutics: A Narrative Review. Diagnostics (Basel). 2021;11(9):1584. doi:10.3390/diagnostics11091584.Papathanasiou KA, Giotaki SG, Vrachatis DA, et al. Molecular Insights in Atrial Fibrillation Pathogenesis and Therapeutics: A Narrative Review. Diagnostics (Basel). 2021;11(9):1584. doi:10.3390/diagnostics11091584.Ревишвили А.Ш., Стребкова Е.Д., Артюхина Е.А. и др. Эффективность торакоскопического лечения непароксизмальных форм фибрилляции предсердий. Вестник аритмологии. 2023;30(3):23-31. doi:10.35336/VA-1160.Revishvili ASh, Strebkova ED, Artyukhina ЕА, et al. The effectiveness of thoracoscopic treatment of non-paroxysmal atrial fibrillation. Journal of Arrhythmology. 2023;30(3):23- 31. (In Russ.) doi:10.35336/VA-1160.Ревишвили А.Ш., Артюхина Е.А., Стребкова Е.Д. и др. Эволюция торакоскопического лечения фибрилляции предсердий: от становления до современного этапа. Комплексные проблемы сердечно-сосудистых заболеваний. 2023;12(2):107-21. doi:10.17802/2306-1278-2023-12-2-107-121.Revishvili AS, Artyukhina EA, Strebkova ED, et al. Evolution of thoracoscopic treatment of atrial fibrillation: from inception to contemporary approaches. Complex Issues of Cardiovascular Diseases. 2023;12(2):107-21. (In Russ.) doi:10.17802/2306-1278-2023-12-2-107-121.Liu L, Huang J, Wei B, et al. Multiomics Analysis of Genetics and Epigenetics Reveals Pathogenesis and Therapeutic Targets for Atrial Fibrillation. Biomed Res Int. 2021;2021: 6644827. doi:10.1155/2021/6644827.Liu L, Huang J, Wei B, et al. Multiomics Analysis of Genetics and Epigenetics Reveals Pathogenesis and Therapeutic Targets for Atrial Fibrillation. Biomed Res Int. 2021;2021: 6644827. doi:10.1155/2021/6644827.Vinciguerra M, Dobrev D, Nattel S. Atrial fibrillation: pathophysiology, genetic and epigenetic mechanisms. Lancet Reg Health Eur. 2024;37:100785. doi:10.1016/j.lanepe.2023.100785.Vinciguerra M, Dobrev D, Nattel S. Atrial fibrillation: pathophysiology, genetic and epigenetic mechanisms. Lancet Reg Health Eur. 2024;37:100785. doi:10.1016/j.lanepe.2023.100785.Wang Q, Dhindsa RS, Carss K, et al. Rare variant contribution to human disease in 281,104Wang Q, Dhindsa RS, Carss K, et al. Rare variant contribution to human disease in 281,104Taliun D, Harris DN, Kessler MD, et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. Nature. 2021;590(7845):290-9. doi:10.1038/s41586-021-03205-y.Taliun D, Harris DN, Kessler MD, et al. Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program. Nature. 2021;590(7845):290-9. doi:10.1038/s41586-021-03205-y.Szustakowski JD, Balasubramanian S, Kvikstad E, et al. Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank. Nat Genet. 2021;53(7):942-8. doi:10.1038/s41588-021-00885-0.Szustakowski JD, Balasubramanian S, Kvikstad E, et al. Advancing human genetics research and drug discovery through exome sequencing of the UK Biobank. Nat Genet. 2021;53(7):942-8. doi:10.1038/s41588-021-00885-0.Paludan-Müller C, Svendsen JH, Olesen MS. The role of common genetic variants in atrial fibrillation. J Electrocardiol. 2016;49(6):864-70. doi:10.1016/j.jelectrocard.2016.08.012.Paludan-Müller C, Svendsen JH, Olesen MS. The role of common genetic variants in atrial fibrillation. J Electrocardiol. 2016;49(6):864-70. doi:10.1016/j.jelectrocard.2016.08.012.Huang X, Li Y, Zhang J, et al. The molecular genetic basis of atrial fibrillation. Hum Genet. 2020;139(12):1485-98. doi:10.1007/s00439-020-02203-w.Huang X, Li Y, Zhang J, et al. The molecular genetic basis of atrial fibrillation. Hum Genet. 2020;139(12):1485-98. doi:10.1007/s00439-020-02203-w.Chen Q, Zheng A, Xu X, et al. Nrf3-Mediated Mitochondrial Superoxide Promotes Cardiomyocyte Apoptosis and Impairs Cardiac Functions by Suppressing Pitx2. Circulation. 2025;151(14):1024-46. doi: 10.1161/circulationaha.124.070286.Chen Q, Zheng A, Xu X, et al. Nrf3-Mediated Mitochondrial Superoxide Promotes Cardiomyocyte Apoptosis and Impairs Cardiac Functions by Suppressing Pitx2. Circulation. 2025;151(14):1024-46. doi: 10.1161/circulationaha.124.070286.Hill MC, Kadow ZA, Li L, et al. A cellular atlas of Pitx2 dependent cardiac development. Development. 2019;146:dev180398. doi:10.1242/dev.180398.Hill MC, Kadow ZA, Li L, et al. A cellular atlas of Pitx2 dependent cardiac development. Development. 2019;146:dev180398. doi:10.1242/dev.180398.Gudbjartsson DF, Arnar DO, Helgadottir A, et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature. 2007;448:353-7. doi:10.1038/nature06007.Gudbjartsson DF, Arnar DO, Helgadottir A, et al. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nature. 2007;448:353-7. doi:10.1038/nature06007.Kany S, Reissmann B, Metzner A, et al. Genetics of atrial fibrillation-practical applications for clinical management: if not now, when and how? Cardiovasc Res. 2021;117(7):1718- 31. doi:10.1093/cvr/cvab153.Kany S, Reissmann B, Metzner A, et al. Genetics of atrial fibrillation-practical applications for clinical management: if not now, when and how? Cardiovasc Res. 2021;117(7):1718- 31. doi:10.1093/cvr/cvab153.Subati T, Kim K, Yang Z, et al. Oxidative Stress Causes Mitochondrial and Electrophysiologic Dysfunction to Promote Atrial Fibrillation in Pitx2+/- Mice. Circ Arrhythm Electrophysiol. 2025;18(3):e013199. doi:10.1161/CIRCEP.124.013199.Subati T, Kim K, Yang Z, et al. Oxidative Stress Causes Mitochondrial and Electrophysiologic Dysfunction to Promote Atrial Fibrillation in Pitx2+/- Mice. Circ Arrhythm Electrophysiol. 2025;18(3):e013199. doi:10.1161/CIRCEP.124.013199.Reyat JS, Sommerfeld LC, O’Reilly M, et al. PITX2 deficiency leads to atrial mitochondrial dysfunction. Cardiovasc Res. 2024;120(15):1907-23. doi:10.1093/cvr/cvae169.Reyat JS, Sommerfeld LC, O’Reilly M, et al. PITX2 deficiency leads to atrial mitochondrial dysfunction. Cardiovasc Res. 2024;120(15):1907-23. doi:10.1093/cvr/cvae169.Collins MM, Ahlberg G, Hansen CV, et al. Early sarcomere and metabolic defects in a zebrafish pitx2c cardiac arrhythmia model. Proc Natl Acad Sci U S A. 2019;116(48):24115-21. doi:10.1073/pnas.1913905116.Collins MM, Ahlberg G, Hansen CV, et al. Early sarcomere and metabolic defects in a zebrafish pitx2c cardiac arrhythmia model. Proc Natl Acad Sci U S A. 2019;116(48):24115-21. doi:10.1073/pnas.1913905116.Sagris M, Vardas EP, Theofilis P, et al. Atrial Fibrillation: Pathogenesis, Predisposing Factors, and Genetics. Int J Mol Sci. 2021;23(1):6. doi:10.3390/ijms23010006.Sagris M, Vardas EP, Theofilis P, et al. Atrial Fibrillation: Pathogenesis, Predisposing Factors, and Genetics. Int J Mol Sci. 2021;23(1):6. doi:10.3390/ijms23010006.Jameson HS, Hanley A, Hill MC, et al. Loss of the Atrial Fibrillation-Related Gene, Zfhx3, Results in Atrial Dilation and Arrhythmias. Circ Res. 2023;133(4):313-29. doi:10.1161/CIRCRESAHA.123.323029.Jameson HS, Hanley A, Hill MC, et al. Loss of the Atrial Fibrillation-Related Gene, Zfhx3, Results in Atrial Dilation and Arrhythmias. Circ Res. 2023;133(4):313-29. doi:10.1161/CIRCRESAHA.123.323029.Wass SY, Smith JD, Chung MK. Connecting the Dots From GWAS to Function in Atrial Fibrillation for ZFHX3. Circ Res. 2023;133(4):330-2. doi:10.1161/CIRCRESAHA.123.323281.Wass SY, Smith JD, Chung MK. Connecting the Dots From GWAS to Function in Atrial Fibrillation for ZFHX3. Circ Res. 2023;133(4):330-2. doi:10.1161/CIRCRESAHA.123.323281.Clausen AG, Vad OB, Andersen JH, Olesen MS. Loss-of-Function Variants in the SYNPO2L Gene Are Associated With Atrial Fibrillation. Front Cardiovasc Med. 2021;8:650667. doi:10.3389/fcvm.2021.650667.Clausen AG, Vad OB, Andersen JH, Olesen MS. Loss-of-Function Variants in the SYNPO2L Gene Are Associated With Atrial Fibrillation. Front Cardiovasc Med. 2021;8:650667. doi:10.3389/fcvm.2021.650667.Martin RI, Babaei MS, Choy MK, et al. Genetic variants associated with risk of atrial fibrillation regulate expression of PITX2, CAV1, MYOZ1, C9orf3 and FANCC. J Mol Cell Cardiol. 2015;85:207-14. doi:10.1016/j.yjmcc.2015.06.005.Martin RI, Babaei MS, Choy MK, et al. Genetic variants associated with risk of atrial fibrillation regulate expression of PITX2, CAV1, MYOZ1, C9orf3 and FANCC. J Mol Cell Cardiol. 2015;85:207-14. doi:10.1016/j.yjmcc.2015.06.005.Rentzsch P, Witten D, Cooper GM, et al. CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 2019;47(D1): D886-D894. doi:10.1093/nar/gky1016.Rentzsch P, Witten D, Cooper GM, et al. CADD: predicting the deleteriousness of variants throughout the human genome. Nucleic Acids Res. 2019;47(D1): D886-D894. doi:10.1093/nar/gky1016.Thorolfsdottir RB, Sveinbjornsson G, Sulem P, et al. Coding variants in RPL3L and MYZAP increase risk of atrial fibrillation. Commun Biol. 2018;1:68. doi:10.1038/s42003-018-0068-9.Thorolfsdottir RB, Sveinbjornsson G, Sulem P, et al. Coding variants in RPL3L and MYZAP increase risk of atrial fibrillation. Commun Biol. 2018;1:68. doi:10.1038/s42003-018-0068-9.Seeger TS, Frank D, Rohr C, et al. Myozap, a novel intercalated disc protein, activates serum response factor-dependent signaling and is required to maintain cardiac function in vivo. Circ Res. 2010;106(5):880-90. doi: 10.1161/CIRCRESAHA.109.213256.Seeger TS, Frank D, Rohr C, et al. Myozap, a novel intercalated disc protein, activates serum response factor-dependent signaling and is required to maintain cardiac function in vivo. Circ Res. 2010;106(5):880-90. doi: 10.1161/CIRCRESAHA.109.213256.Nielsen JB, Fritsche LG, Zhou W, et al. Genome-wide Study of Atrial Fibrillation Identifies Seven Risk Loci and Highlights Biological Pathways and Regulatory Elements Involved in Cardiac Development. Am J Hum Genet. 2018;102(1):103-15. doi:10.1016/j.ajhg.2017.12.003.Nielsen JB, Fritsche LG, Zhou W, et al. Genome-wide Study of Atrial Fibrillation Identifies Seven Risk Loci and Highlights Biological Pathways and Regulatory Elements Involved in Cardiac Development. Am J Hum Genet. 2018;102(1):103-15. doi:10.1016/j.ajhg.2017.12.003.El-Harasis MA, Yoneda ZT, Anderson KC, et al. Ablation for Atrial Fibrillation in Patients With Rare Pathogenic Variants in Cardiomyopathy and Arrhythmia Genes. JACC Clin Electrophysiol. 2024;10(11):2359-70. doi:10.1016/j.jacep.2024.06.035.El-Harasis MA, Yoneda ZT, Anderson KC, et al. Ablation for Atrial Fibrillation in Patients With Rare Pathogenic Variants in Cardiomyopathy and Arrhythmia Genes. JACC Clin Electrophysiol. 2024;10(11):2359-70. doi:10.1016/j.jacep.2024.06.035.Akhtar MM, Lorenzini M, Cicerchia M, et al. Clinical Phenotypes and Prognosis of Dilated Cardiomyopathy Caused by Truncating Variants in the TTN Gene. Circ Heart Fail. 2020;13(10):e006832. doi:10.1161/CIRCHEARTFAILURE.119.006832.Akhtar MM, Lorenzini M, Cicerchia M, et al. Clinical Phenotypes and Prognosis of Dilated Cardiomyopathy Caused by Truncating Variants in the TTN Gene. Circ Heart Fail. 2020;13(10):e006832. doi:10.1161/CIRCHEARTFAILURE.119.006832.Virk ZM, El-Harasis MA, Yoneda ZT, et al. Clinical Characteristics and Outcomes in Patients With Atrial Fibrillation and Pathogenic TTN Variants. JACC Clin Electrophysiol. 2024;10(11):2445-57. doi:10.1016/j.jacep.2024.07.029.Virk ZM, El-Harasis MA, Yoneda ZT, et al. Clinical Characteristics and Outcomes in Patients With Atrial Fibrillation and Pathogenic TTN Variants. JACC Clin Electrophysiol. 2024;10(11):2445-57. doi:10.1016/j.jacep.2024.07.029.Nielsen JB, Thorolfsdottir RB, Fritsche LG, et al. Biobank-driven genomic discovery yields new insight into atrial fibrillation biology. Nat Genet. 2018;50(9):1234-9. doi:10.1038/s41588-018-0171-3.Nielsen JB, Thorolfsdottir RB, Fritsche LG, et al. Biobank-driven genomic discovery yields new insight into atrial fibrillation biology. Nat Genet. 2018;50(9):1234-9. doi:10.1038/s41588-018-0171-3.Yoneda ZT, Anderson KC, Quintana JA, et al. Early-Onset Atrial Fibrillation and the Prevalence of Rare Variants in Cardiomyopathy and Arrhythmia Genes. JAMA Cardiol. 2021;6(12):1371-9. doi:10.1001/jamacardio.2021.3370.Yoneda ZT, Anderson KC, Quintana JA, et al. Early-Onset Atrial Fibrillation and the Prevalence of Rare Variants in Cardiomyopathy and Arrhythmia Genes. JAMA Cardiol. 2021;6(12):1371-9. doi:10.1001/jamacardio.2021.3370.Ghazizadeh Z, Kiviniemi T, Olafsson S, et al. Metastable atrial state underlies the primary genetic substrate for MYL4 mutation-associated atrial fibrillation. Circulation 2020;141:301- 12. doi:10.1161/CIRCULATIONAHA.119.044268.Ghazizadeh Z, Kiviniemi T, Olafsson S, et al. Metastable atrial state underlies the primary genetic substrate for MYL4 mutation-associated atrial fibrillation. Circulation 2020;141:301- 12. doi:10.1161/CIRCULATIONAHA.119.044268.Choi SH, Weng LC, Roselli C, et al. DiscovEHR study and the NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium. Association Between Titin Loss-of-Function Variants and Early-Onset Atrial Fibrillation. JAMA. 2018;320(22):2354-64. doi:10.1001/jama.2018.18179.Choi SH, Weng LC, Roselli C, et al. DiscovEHR study and the NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium. Association Between Titin Loss-of-Function Variants and Early-Onset Atrial Fibrillation. JAMA. 2018;320(22):2354-64. doi:10.1001/jama.2018.18179.Goodyer WR, Dunn K, Caleshu C, et al. Broad genetic testing in a clinical setting uncovers a high prevalence of titin loss-of-function variants in very early onset atrial fibrillation. Circ Genom Precis Med. 2019;12:e002713. doi:10.1161/CIRCGEN.119.002713.Goodyer WR, Dunn K, Caleshu C, et al. Broad genetic testing in a clinical setting uncovers a high prevalence of titin loss-of-function variants in very early onset atrial fibrillation. Circ Genom Precis Med. 2019;12:e002713. doi:10.1161/CIRCGEN.119.002713.Choi SH, Jurgens SJ, Weng LC, et al. Monogenic and Polygenic Contributions to Atrial Fibrillation Risk: Results From a National Biobank. Circ Res. 2020;126(2):200-9. doi:10.1161/CIRCRESAHA.119.315686.Choi SH, Jurgens SJ, Weng LC, et al. Monogenic and Polygenic Contributions to Atrial Fibrillation Risk: Results From a National Biobank. Circ Res. 2020;126(2):200-9. doi:10.1161/CIRCRESAHA.119.315686.Choi SH, Jurgens SJ, Xiao L, et al. Sequencing in over 50,000 cases identifies coding and structural variation underlying atrial fibrillation risk. Nat Genet. 2025;57(3):548-62. doi:10.1038/s41588-025-02074-9.Choi SH, Jurgens SJ, Xiao L, et al. Sequencing in over 50,000 cases identifies coding and structural variation underlying atrial fibrillation risk. Nat Genet. 2025;57(3):548-62. doi:10.1038/s41588-025-02074-9.Galán-Vidal J, Socuéllamos PG, Baena-Nuevo M, et al. A novel loss-of-function mutation of the voltage-gated potassium channel Kv10.2 involved in epilepsy and autism. Orphanet J Rare Dis. 2022;17(1):345. doi:10.1186/s13023-022-02499-z.Galán-Vidal J, Socuéllamos PG, Baena-Nuevo M, et al. A novel loss-of-function mutation of the voltage-gated potassium channel Kv10.2 involved in epilepsy and autism. Orphanet J Rare Dis. 2022;17(1):345. doi:10.1186/s13023-022-02499-z.Elhanafy E, Ahangar AA, Roth R, et al. Elucidating the differential impacts of equivalent gating-charge mutations in voltage-gated sodium channels. 2024:2024.09.09.612021. doi:10.1101/2024.09.09.612021.Elhanafy E, Ahangar AA, Roth R, et al. Elucidating the differential impacts of equivalent gating-charge mutations in voltage-gated sodium channels. 2024:2024.09.09.612021. doi:10.1101/2024.09.09.612021.Brunklaus A, Brünger T, Feng T, et al. The gain of function SCN1A disorder spectrum: novel epilepsy phenotypes and therapeutic implications. Brain. 2022;145(11):3816-31. doi:10.1093/brain/awac210.Brunklaus A, Brünger T, Feng T, et al. The gain of function SCN1A disorder spectrum: novel epilepsy phenotypes and therapeutic implications. Brain. 2022;145(11):3816-31. doi:10.1093/brain/awac210.Dahlberg P, Pozzi S, Bulmer L, et al. Clinical and electrophysiological characterization of a SCN5A gain-of-function mutation associated with CPVT-like arrhythmia. J Mol Cell Cardiol. 2025;203:47-58. doi:10.1016/j.yjmcc.2025.04.001.Dahlberg P, Pozzi S, Bulmer L, et al. Clinical and electrophysiological characterization of a SCN5A gain-of-function mutation associated with CPVT-like arrhythmia. J Mol Cell Cardiol. 2025;203:47-58. doi:10.1016/j.yjmcc.2025.04.001.Wilde AAM, Amin AS. Clinical Spectrum of SCN5A Mutations: Long QT Syndrome, Brugada Syndrome, and Cardiomyopathy. JACC Clin Electrophysiol. 2018;4(5):569-79. doi:10.1016/j.jacep.2018.03.006.Wilde AAM, Amin AS. Clinical Spectrum of SCN5A Mutations: Long QT Syndrome, Brugada Syndrome, and Cardiomyopathy. JACC Clin Electrophysiol. 2018;4(5):569-79. doi:10.1016/j.jacep.2018.03.006.Cadena-Ullauri S, Guevara-Ramírez P, Ruiz-Pozo VA, et al. Genomic analysis of an Ecuadorian individual carrying an SCN5A rare variant. BMC Cardiovasc Disord. 2024;24(1): 388. doi:10.1186/s12872-024-04049-w.Cadena-Ullauri S, Guevara-Ramírez P, Ruiz-Pozo VA, et al. Genomic analysis of an Ecuadorian individual carrying an SCN5A rare variant. BMC Cardiovasc Disord. 2024;24(1): 388. doi:10.1186/s12872-024-04049-w.Olesen MS, Yuan L, Liang B, et al. High prevalence of long QT syndrome-associated SCN5A variants in patients with early-onset lone atrial fibrillation. Circ Cardiovasc Genet. 2012;5(4):450-9. doi:10.1161/CIRCGENETICS.111.962597.Olesen MS, Yuan L, Liang B, et al. High prevalence of long QT syndrome-associated SCN5A variants in patients with early-onset lone atrial fibrillation. Circ Cardiovasc Genet. 2012;5(4):450-9. doi:10.1161/CIRCGENETICS.111.962597.Darbar D, Kannankeril PJ, Donahue BS, et al. Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation. Circulation. 2008;117:1927-35. doi:10.1161/CIRCULATIONAHA.107.757955.Darbar D, Kannankeril PJ, Donahue BS, et al. Cardiac sodium channel (SCN5A) variants associated with atrial fibrillation. Circulation. 2008;117:1927-35. doi:10.1161/CIRCULATIONAHA.107.757955.Man JCK, Bosada FM, Scholman KT, et al. Variant Intronic Enhancer Controls SCN10Ashort Expression and Heart Conduction. Circulation. 2021;144(3):229-242. doi:10.1161/circulationaha.121.054083.Man JCK, Bosada FM, Scholman KT, et al. Variant Intronic Enhancer Controls SCN10Ashort Expression and Heart Conduction. Circulation. 2021;144(3):229-242. doi:10.1161/circulationaha.121.054083.Xue Y, Chidiac C, Herault Y, Gaveriaux-Ruff C. Pain behavior in SCN9A (Nav1.7) and SCN10A (Nav1.8) mutant rodent models. Neurosci Lett. 2021;753:135844. doi:10.1016/j.neulet.2021.135844.Xue Y, Chidiac C, Herault Y, Gaveriaux-Ruff C. Pain behavior in SCN9A (Nav1.7) and SCN10A (Nav1.8) mutant rodent models. Neurosci Lett. 2021;753:135844. doi:10.1016/j.neulet.2021.135844.Jabbari J, Olesen MS, Yuan L, et al. Common and rare variants in SCN10A modulate the risk of atrial fibrillation. Circ Cardiovasc Genet. 2015;8(1):64-73. doi:10.1161/HCG.0000000000000022.Jabbari J, Olesen MS, Yuan L, et al. Common and rare variants in SCN10A modulate the risk of atrial fibrillation. Circ Cardiovasc Genet. 2015;8(1):64-73. doi:10.1161/HCG.0000000000000022.Li E, van der Heyden MAG. The network of cardiac KIR2.1: its function, cellular regulation, electrical signaling, diseases and new drug avenues. Naunyn Schmiedebergs Arch Pharmacol. 2024;397(9):6369-89. doi:10.1007/s00210-024-03116-5.Li E, van der Heyden MAG. The network of cardiac KIR2.1: its function, cellular regulation, electrical signaling, diseases and new drug avenues. Naunyn Schmiedebergs Arch Pharmacol. 2024;397(9):6369-89. doi:10.1007/s00210-024-03116-5.Kanai M, Toyohara K, Shoda M. Familial atrial rapid fibrillation associated with double mutations of SCN5A and KCNQ1. Cardiol Young. 2021;31(8):1356-8. doi:10.1017/S1047951121000615.Kanai M, Toyohara K, Shoda M. Familial atrial rapid fibrillation associated with double mutations of SCN5A and KCNQ1. Cardiol Young. 2021;31(8):1356-8. doi:10.1017/S1047951121000615.Hateley S, Lopez-Izquierdo A, Jou CJ, et al. The history and geographic distribution of a KCNQ1 atrial fibrillation risk allele. Nat Commun. 2021;12(1):6442. doi:10.1038/s41467-021-26741-7.Hateley S, Lopez-Izquierdo A, Jou CJ, et al. The history and geographic distribution of a KCNQ1 atrial fibrillation risk allele. Nat Commun. 2021;12(1):6442. doi:10.1038/s41467-021-26741-7.Meyer KM, Malhotra N, Kwak JS, El Refaey M. Relevance of KCNJ5 in Pathologies of Heart Disease. Int J Mol Sci. 2023;24(13):10849. doi:10.3390/ijms241310849.Meyer KM, Malhotra N, Kwak JS, El Refaey M. Relevance of KCNJ5 in Pathologies of Heart Disease. Int J Mol Sci. 2023;24(13):10849. doi:10.3390/ijms241310849.Roselli C, Chaffin MD, Weng LC, et al. Multi-ethnic genome-wide association study for atrial fibrillation. Nat Genet. 2018;50(9):1225-33. doi:10.1038/s41588-018-0133-9.Roselli C, Chaffin MD, Weng LC, et al. Multi-ethnic genome-wide association study for atrial fibrillation. Nat Genet. 2018;50(9):1225-33. doi:10.1038/s41588-018-0133-9.Diness JG, Skibsbye L, Simó-Vicens R, et al. Termination of Vernakalant-Resistant Atrial Fibrillation by Inhibition of Small-Conductance Ca2+-Activated K+ Channels in Pigs. Circ Arrhythm Electrophysiol. 2017;10(10):e005125. doi:10.1161/CIRCEP.117.005125.Diness JG, Skibsbye L, Simó-Vicens R, et al. Termination of Vernakalant-Resistant Atrial Fibrillation by Inhibition of Small-Conductance Ca2+-Activated K+ Channels in Pigs. Circ Arrhythm Electrophysiol. 2017;10(10):e005125. doi:10.1161/CIRCEP.117.005125.

The authors declare that there are no conflicts of interest present.